This webcast will discuss the options available to patients and give a comprehensive review of the data from the EXCEL and NOBLE trials. Conversations will also highlight some of the varied treatments currently used in Europe and what cardiac interventionists in the United States can anticipate.

This program will look at TAVR performance to have a clear understanding of the surgical risk strata identifying extreme, high, intermediate, and low risk patients. Throughout the discussion the participants will gain knowledge and tips on improving the selection for TAVR patients and the future of TAVR in low and intermediate risk patients.

During this informative webcast, listen to experts tackle the important topic of how best to revascularize patients with left main disease. Learn about data from the two main trials, EXCEL and NOBLE, in which patients with simple or moderate coronary artery disease with left main component are studied. Patients are compared randomly as either undergoing PCI or surgery.

This program will look at the correct timing and modality of transition from intravenous to oral platelet inhibition in patients. Lessons learned from the PHOENIX and CHAMPION study and the outcomes of establishing potent P2Y12 inhibition with medication will be discussed.

During this webcast, experts in the field discuss results from the latest stent trials. Find out about data from the trials and how it guides current practice, as well as the future of the next generation DES.

In this webcast experts in the field of cardiology discuss the future of low risk TAVR procedures and new criteria for TAVR use in patients, including STS scores, frailty, and disability for enrollment in a low risk trial.